Drug Trial Radar · NCT05817214
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Apr 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Feb 16, 2023
Primary completion
Nov 30, 2025
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Zhongnan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Akeso Biopharma Co., Ltd.
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test a new treatment combination including cadonilimab, anlotinib and granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent, metastasis and persistent cervical cancer. The main questions it aims to answer are: * The efficacy of this combination in R/M/P CC; * The tolerance of this combination in R/M/P CC; * Possible biomarker of treatment response for this combination. Participants will receive cadonilimab of 10mg/kg every three weeks at day 1, take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break and subcutaneously injection of GM-CSF (200ug) from day 1 to day 14, then also take a 7-days break. This treatment will continue until progression or intolerable toxicity or withdraw of participants and it will last for no longer than 2 years.
Conditions
- Cervical Cancer
Interventions
CadonilimabDrug
All Participants will receive cadonilimab of 10mg/kg every three weeks at day 1
AnlotinibDrug
All Participants will take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break.
Granulocyte-Macrophage Colony-Stimulating FactorDrug
All Participants will have subcutaneously injection of granulocyte-macrophage colony-stimulating factor from day 1 to day 14, then take a 7 days break.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.